Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System

Multiple Sclerosis Clinical Trial

— CARTinNS  

Official title:

An Open Label Clinical Trial to Evaluate the Safety and Efficacy of CT103A Cells for the Treatment of Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04561557
• Other study ID #: CARTinNS
• Status: Recruiting
• Phase: Early Phase 1
• Start date: September 22, 2020
• Est. completion date: May 31, 2027

Study information

• Verified date: May 2024
• Source: Tongji Hospital
• Contact: Chuan Qin, MD
• Phone: 86-27-83663337
• Email: qinchuan712[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Antibody-mediated inflammatory diseases of the nervous system (also known as autoimmune diseases of the nervous system) are autoimmune diseases in which autoimmune cells and immune molecules attack the nervous system as the main pathogenic mechanism. In the immune response, pathogenic antibodies acting on autoantigens of the nervous system are collectively referred to as autoantibodies of the nervous system, and antibody-mediated inflammatory diseases of the nervous system can occur in the central nervous system, peripheral nervous system, and neuromuscular junctions, and muscles. In this study, we will recruit eight kinds of autoimmune diseases of nervous system including Neuromyelitis Optica Spectrum Disorder (NMOSD), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), idiopathic inflammatory myopathyand (IIM), multiple sclerosis (MS), autoimmune encephalitis (AE), Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) and POEMS Syndrome. B-cell maturation antigen (BCMA) is expressed on the surface of plasma cells, thus making it an ideal target for targeted therapies. Chimeric antigen receptor (CAR) T cells against BCMA offers another potential therapeutic option to eliminate plasma cells in patients with neurological autoimmune diseases driven by abnormal antibody who still suffer recurrent attacks from conventional treatments. In the current study, the safety and efficacy of a novel CAR-T cell therapy using CT103A cells, are evaluated in patients with relapsed/refractory antibody-mediated idiopathic inflammatory diseases.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 36
• Est. completion date: May 31, 2027
• Est. primary completion date: February 22, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Male or female subjects aged 18-75 years (including 18 and 75 years);

2. Subjects with Relapsing/refractory Antibody-mediated inflammatory diseases of the

nervous system without effective treatment, including:

1. Subjects must be diagnosed as AQP4-IgG-positive NMOSD defined by 2015 criteria of IPND NMOSD and meet the following requirements: i. At least one kind of immunosuppressant has been used for more than one year with poorly-controlled symptoms; ii. Clinical evidence of at least two relapses in the last 12 months or three relapses in the last 24 months and one relapse in the preceding 12 months before screening.

2. Subjects with MG with positive abnormal antibody, MG-ADL total score = 6 points, MGFA classification II-IV defined by 2020 MGFA diagnostic criteria and meet the following requirement: i. At least one kind of immunosuppressant for standardized treatment for more than 1 year, and have one of the following poor control conditions: 1) continuous inability to affect daily life; 2) Exacerbation of MG symptoms and/or crisis attacks still occur despite standard treatment; 3) Inability to tolerate immunosuppressive therapy ii. Requires plasma exchange or maintenance therapy with IV gamma globulin

3. Subjects with CIDP with positive abnormal antibodies, INCAT disability scale with total score of 2-9 defined by 2021 EAN/PNS diagnostic criteria and meet the following requirement: i. Standardized use of at least one first-line therapy for more than 3 months (cortisol hormone therapy, gamma globulin or plasma exchange therapy) with poorly-controlled symptoms. ii. Inability to tolerate cortisol hormones, gamma globulin, and plasmapheresis because of side effects or other conditions

4. Subjects were diagnosed with relapsing/refractory antibody-mediated inflammatory myopathy, such as IMNM with positive SRP or HMGCR antibody, have at least one proximal limb muscle strength less than grade 4 and elevated creatine kinase defined by 2016 ENMC diagnostic criteria and meet one of the following requirements: i. After at least 1 month of corticosteroid therapy and standardized use of at least one immunosuppressant/modulator (eg, azathioprine, methotrexate, mycophenolate mofetil, cyclosporine, tacrolimus, Cyclophosphamide, leflunomide, intravenous gamma globulin, etc.) for more than 3 months with poorly-controlled symptoms. ii. Inability to tolerate the above traditional regimens due to side effects or other conditions;

5. Subjects were diagnosed with PMS (including PPMS and SPMS) or RMS according to the 2017 revision of the McDonald diagnostic criteria;EDSS score between 2 to 7 points inclusive, at screening. Subjects with RMS should meet one of the following requirements after standard therapy: i. at least two relapses in the last two years before screening. ii. at least one relapse in the last one year before screening. iii. positive Gd-enhancing MRI in the last one year before screening. f. Subjects were diagnosed with POEMS syndrome according to the 2021 revised IMWG diagnostic criteria and meet all of the following requirements: i. bone marrow involvement; ii. no response to traditional regimens treatment including corticosteroid, chemotherapy, protease inhibitor or inability to tolerate the above traditional regimens; iii. Have measurable lesions (refer to the 2021 revised IMWG standard) iv. VEGF > 2 ULN; v. ECOG score =1; vi. ONLS score =1. g. Subjects were diagnosed with autoimmune encephalitis according to the 2016 International Diagnostic Criteria for Autoimmune Encephalitis and meet all of the following requirements: i. at least one pathogenic antibody positive; ii. previously standardized use of corticosteroid, at least one immunosuppressant/modulator, including CD20 monoclonal antibody with poorly-controlled symptoms or intolerance; iii. onset of autoimmune encephalitis within 3 months prior to screening; iv. mRS Score =2 or CASE score =4. h. Subjects were diagnosed with MOGAD according to the 2023 International MOGAD Diagnostic criteria and meet all of the following requirements: i. a documented positive serum MOG Ab test using a cell-based assay (CBA); ii mRS Score =2; iii previously standardized use of corticosteroid, at least one immunosuppressant/modulator, including CD20 monoclonal antibody with poorly-controlled symptoms or intolerance.

3. All acute toxic reactions resolved to baseline or = grade 1 assessed using NCI-CTCAE v5.0 except the ones adjudicated by the investigator to pose no risks on subjects.

4. Enrolled subjects must have satisfactory organ function and laboratory findings as defined by the following:i. Blood tests: absolute neutrophil count = 2×109/L (or normal lower limit set by the central lab of the institution), platelets = 100 × 109/L, and hemoglobin = 100 g/L; ii. Liver function: total serum bilirubin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be = 1.5x the institutional normal upper limit (ULN); iii. Kidney function: CrCl = 60 ml/min/1.73m2 (according to the following Cockcroft-Gault formula); iv. Electrolytes: blood potassium = 3.0 mmol/L; blood calcium = 2.0 mmol/L, blood magnesium = 0.5 mmol/L; v. Coagulation function: fibrinogen = 1.0 g/L; APTT = ULN + 10s; PT = ULN + 3s.

5. Blood oxygen saturation > 91% in resting state.

6. Echocardiography suggests LVEF= 50%.

7. Expected life expectancy = 12 weeks as assessed by the investigator.

8. After signing the informed consent form, subjects and their partners must be willing to use effective and reliable method of contraception, devices or medicines, within one year after CT103A cells infusion (excluding contraception safety periods).

9. Subjects must provide written informed consent before the study begin.

Exclusion Criteria:

1. Patients do not have adequate mononuclear cells without mobilization for CAR-T cell manufacturing.

2. History of autoimmune hemolytic disease.

3. History of solid organ transplantation.

4. Patients were treated with alemtuzumab within 6 months prior to apheresis. Patients were treated with fludarabine or cladribine within 3 months prior to apheresis.

5. Patients with Papovaviruses infection.

6. Patients have been diagnosed with malignancies in the last 2 years prior to screening except for non-melanoma skin cancer, stage I cancers with complete resection and low risk of relapse, localized prostate cancer post-treatments, biopsy-confirmed in situ cervical cancer, or squamous epithelial lesion by PAP smear.

7. Chronic and active hepatitis B (HBV), hepatitis C (HCV), Human Immunodeficiency Virus (HIV) infection, CMV or syphilis infections concurrently.

8. MG crisis was not effectively controlled within 2 weeks before enrollment.

9. Known history of primary immunodeficiency (innate or acquired).

10. Patients with severe impaired cardiac function, including but not limited to the following: unstable angina, myocardial infarction (within 6 months before enrollment), congestive heart failure (=Grade III by NYHA), severe ventricular arrhythmia.

11. Cerebrovascular accidents, including transient ischemic attack or stroke history, occurred within 6 months before enrollment.

12. Major operation or surgical treatment caused by any reason within 4 weeks before enrollment.

13. Any serious and/or uncontrolled comorbidities which may interfere with the evaluation during the study in the opinion of the investigator

14. Previous treatments: History of thymectomy within 12 months prior to CT103A infusion;

15. History of psychoactive drug abuse and failed to withdraw, or have a history of psychiatric disorders.

16. Prone to allergies or history of serious allergy.

17. Pregnant or lactating women.

18. Patients with other conditions adjudicated by the investigator as unsuitable for enrollment. Criteria for lymphodepletion and CAR-T cells infusion: Before lymphocyte depletion and CAR-T cells infusion, patients are evaluated and those

meeting the following criteria cannot be included:

1. Blood tests: neutrophil count < 2 × 109/L, platelet count < 50 × 10^9/L;

2. Oxygen inhalation is required to maintain blood oxygen saturation = 91%;

3. Patients have the following conditions, including but not limited to: new arrhythmia cannot be controlled by drugs; hypotension requiring pressor drugs; bacterial, fungal or viral infection requiring intravenous antibiotic treatment; creatinine clearance rate < 50 ml/min ;

4. Patients require maintenance support treatment within one week to meet the criteria for lymphodepletion or CAR T cell infusion.

5. Cell infusion is delayed > 7 days after lymphodepletion for any reason;

6. Patients with other conditions adjudicated by the investigator as unsuitable for lymphodepletion or cell infusion.

Related Conditions & MeSH terms

• Autoimmune Diseases
• Autoimmune Diseases of the Nervous System
• Autoimmune Encephalitis
• Chronic Inflammatory Demyelinating Polyradiculoneuropathy
• Encephalitis
• Idiopathic Inflammatory Myopathies
• Multiple Sclerosis
• Myasthenia Gravis
• Myositis
• Nervous System Diseases
• Neuromyelitis Optica
• Neuromyelitis Optica Spectrum Disorder
• POEMS Syndrome
• Polyradiculoneuropathy
• Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Intervention

Biological:
• CT103A cells
Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to manufacture CT103A cells, during which cyclophosphamide will be administered for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with CT103A cells by intravenous (IV) infusion. The initial dose of 0.5×10^6 CAR+ T cells/kg will be infused on day 0.

Drug:
• Cyclophosphamide and fludarabine
Subjects will receive one 3-day cycle of lymphodepletion starting 4 days prior to CT103A infusion on Day 0. Subjects will be given IV infusion of cyclophosphamide 500 mg/m2/day on day -4, -3 and -2, and fludarabine 30 mg/m2 over 30 minutes administered immediately after cyclophosphamide.

Locations

Country	Name	City	State
China	Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology	Wuhan	Hubei

Sponsors (2)

Lead Sponsor	Collaborator
Tongji Hospital	Nanjing IASO Biotechnology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	NMOSD: Annualized relapse rate (ARR)	the number of attacks divided by observed year after CT103A cells infusion	Up to 2 years post CT103A infusion
Other	NMOSD: Accumulated total active MRI lesions	the number of accumulate total active MRI lesions after CT103A infusion	Up to 2 years post CT103A infusion
Other	NMOSD: Expanded Disability Status Scale (EDSS) score	EDSS and its associated functional system (FS) score provide a system for quantifying disability and monitoring changes in the level of disability over time. EDSS is a scale for assessing neurologic impairment in multiple sclerosis (MS). It consists of 7 FS (visual FS, brainstem FS, pyramidal FS, cerebellar FS, sensory FS, bowel and bladder FS, and cerebral FS) which are used to derive EDSS score ranging from 0 (normal neurological exam) to 10 (death from MS). A negative change from baseline indicates improvement. A participant was considered to have a worsening in overall EDSS score of at least 2 if baseline EDSS score was 0, or at least 1 point if baseline EDSS score is 1 to 5, or at least 0.5 point if baseline EDSS score is 5.5 or more.	Up to 2 years post CT103A infusion
Other	NMOSD: Modified Rankin Scale	Modified Rankin Scale (mRS) is a profoundly valid and reliable measure of disability and is broadly utilized for assessing stroke outcomes and degree of disability. We characterized a favorable outcome as mRS ranging from zero up to two, while unfavorable outcome ranging for 3 up to 6.	Up to 2 years post CT103A infusion
Other	NMOSD: Visual acuity	Corrected visual acuity is determine by Snellen E chart held at a distance of 5 meters. Higher score indicates better vision.	Up to 2 years post CT103A infusion
Other	MG: Quantitative Myasthenia Gravis Score (QMG)	The QMG score is a 13-item scale used to quantify disease severity in myasthenia gravis. The scale measures ocular, bulbar, respiratory, and limb function, grading each finding, and ranges from 0 (no myasthenic findings) to 39 (maximal myasthenic deficits).	Up to 2 years post CT103A infusion
Other	MG: Myasthenia Gravis Activities if Daily Living (MG-ADL) Score	The MG-ADL is an eight-question survey of symptom severity, with each response graded from 0 (normal) to 3 (most severe). Two questions concern ocular, three oropharyngeal, one respiratory, and two extremity functions. Cumulative MG-ADL scores range from 0 to 24	Up to 2 years post CT103A infusion
Other	CIDP: Inflammatory Neuropathy Cause and Treatment (INCAT) Score	The INCAT score comprises two parts, the arm score and the leg score. Based on a patient's level of impairment in their arms and legs, each part is scored between 0 and 5 points, resulting in an INCAT total score between 0 and 10.	Up to 2 years post CT103A infusion
Other	CIDP: Medical Research Council (MRC) muscle function Score	The MRC score system for testing and grading of muscle function aims to provide a standardized and objective way to assess muscle function. It ranges from 0 to 5.	Up to 2 years post CT103A infusion
Other	CIDP: Assess changes in nerve conduction test results	Including motor nerve distal latency, proximal latency, compound muscle motor potential (CMAP), motor nerve conduction velocity, sensory nerve conduction velocity, sural nerve potential	Up to 2 years post CT103A infusion
Other	IMNM: Manual Muscle Testing (MMT) Score	For MMT score, 16 muscle groups/ motions will be tested (not individual muscles). 14 of these are tested bilaterally.	Up to 2 years post CT103A infusion
Other	IMNM: Assess the changes in serum creatine kinase levels in patients with IMNM before and after treatment.	If the creatine kinase level drops to twice the upper limit of normal or below, it is defined as effective, and the effective rate is calculated	Up to 2 years post CT103A infusion
Other	IMNM: Muscle MRI	Calculating the hyperintensity of muscle MRI T2/STIR sequence in patients with IMNM	Up to 2 years post CT103A infusion
Other	36-item Short Form Generic Health Survey (SF-36) score	SF-36 will used to understand the health related quality-of -life of the subjects after CT103A infusion. The eight health concepts: limitations in physical activities because of health problems; limitations in social activities because of physical or emotional problems; limitations in usual role activities because of physical health problems; bodily pain; general mental health (psychological distress and well-being); limitations in usual role activities because of emotional problems; vitality (energy and fatigue); and general health perceptions will be searched. These outcomes will be grouped as physical component summary and mental component summary. The norm data is 0-100, the health related quality of life is increases as the scores are increased. The average score is 50.	Up to 2 years post CT103A infusion
Other	EuroQol-five dimensions (EQ-SD) score	Health status is measured with the EuroQuality of Life Five Dimensions (EQ-5D) after CT103A infusion, which includes five dimensions and is used to evaluate the quality of life of sepsis survivors. They are mobility, self-care, usual activities, discomfort or pain and depression or anxiety. Levels are coded 1-5 and a total score is then generated. Results for the demographic measured will be displayed as a percentage value.	Up to 2 years post CT103A infusion
Other	Visual analogue scale (VAS) pain score	usual visual analog scale (VAS) of pain is used to evaluate pain after CT103A infusion (line from 0: no pain to 10:worst pain)	Up to 2 years post CT103A infusion
Other	Annual hospitalization rates	The number of In-patient hospitalization is defined as a stay in hospital that goes beyond midnight of the first day of admission.	Up to 2 years post CT103A infusion
Other	Cytokines release after CT103A infusion	Changes of concentration( pg/mL) of cytokines ( such as ferritin, CRP, IL-6 and procalcitonin) will be analyzed after CT103A cells infusion.	Up to 2 years post CT103A infusion
Other	Immunogenicity of CT103A cells	Anti-drug antibodies (ADA) against CAR on CT103A cells will be analyzed after CT103A cells infusion.	Up to 2 years post CT103A infusion
Other	Detection of RCL	Levels of replication competent lentivirus (RCL) will be monitored after CT103A cells infusion.	Up to 2 years post CT103A infusion
Other	Profiling of cell subtypes	Changes in cells in infused CAR T products, blood and CSF (including proportion of CD3+ T cells, CD3+CD4+ T cells and CD3+CD8+ T cells, ratio of CD4+ T/CD8+T, and single-cell sequencing) will be analyzed after CT103A cells infusion.	Up to 2 years post CT103A infusion
Other	MS: Annualized Relapse Rate (ARR)	Annualized relapse rate (ARR): Number of MS relapses divided by observed year after CT103A cells infusion	Up to 2 years post CT103A infusion
Other	MS: Time to first relapse	Time from CT103A infusion to the first relapse of MS	Up to 2 years post CT103A infusion
Other	MS: Number of T1 Gadolinium (Gd)	The changes of enhancing Lesions as detected by brain Magnetic Resonance Imaging (MRI)	Up to 2 years post CT103A infusion
Other	MS: Annualized rate of T2 lesions	Annualized rate of T2 lesions: Number of New, and/or Enlarging T2 Hyperintense Lesions as detected by MRI divided by observed year after CT103A cells infusion	Up to 2 years post CT103A infusion
Other	MS: Percent Change in T2 lesions volume	The percent change of T2 lesions volume as detected by MRI from the baseline	Up to 2 years post CT103A infusion
Other	MS: Change in EDSS	EDSS and its associated functional system (FS) score provide a system for quantifying disability and monitoring changes in the level of disability over time. EDSS is a scale for assessing neurologic impairment in multiple sclerosis (MS).	Up to 2 years post CT103A infusion
Other	MS: Percent of NEDA-3	The no evidence of disease activity-3 (NEDA-3), defined as no relapse, no disability worsening, and no MRI activity	Up to 2 years post CT103A infusion
Other	MS: 3-month CDP	Time to onset of 3-month CDP as assessed by EDSS score	Up to 3 months post CT103A infusion
Other	MS: 6-month CDP	Time to onset of 6-month CDP as assessed by EDSS score	Up to 6 months post CT103A infusion
Other	MS: Patient Reported Outcomes (PRO)	Including Fatigue Symptoms and Impacts Questionnaire -Relapsing Multiple Sclerosis (FSIQ-RMS), General Anxiety Disorder Scale (GAD-7), Patient Health Questionnaire (PHQ-9), Health Utilities Index (HUI-III), Multiple Sclerosis Impact Scale (MSIS-29).	Up to 2 years post CT103A infusion
Other	POEMS syndrome: Overall Response Rate (ORR)	Definition of Response: There is a one-point improvement in ECOG performance score; and/or; = 50% reduction in ONLS score.	Up to 2 years post CT103A infusion
Other	POEMS syndrome: Hematological response rate	Hematological response rate: Percentage of subjects who achieved partial response (PR) or better according to 2021 IMWG Uniform Response Criteria.	Up to 2 years post CT103A infusion
Other	POEMS syndrome: Neural response rate	Definition of Neural Response: a) There is a one-point improvement in ONLS score; and/or b) = 15% reduction in mNIS+7 score.	Up to 2 years post CT103A infusion
Other	POEMS syndrome: Change in VEGF	The changes of VEGF levels after CT103A cells infusion.	Up to 2 years post CT103A infusion
Other	POEMS syndrome: PET response rate	PET response rate: Percentage of subjects who achieved response according to 2021 IMWG Uniform Response Criteria.	Up to 2 years post CT103A infusion
Other	POEMS syndrome: Response rate of other organs	Percentage of subjects who achieved response of other organs.	Up to 2 years post CT103A infusion
Other	AE: Time to =1point improvement in modified Rankin score (mRS)	Time to =1point improvement in modified Rankin score (mRS) from baseline without rescue therapy.	Up to 2 years post CT103A infusion
Other	AE: Time to first relapse	Time to first relapse: Time from CT103A infusion to the first relapse of AE (days).	Up to 2 years post CT103A infusion
Other	AE: Epilepsy	The time to seizure-free (Patients with autoimmune encephalitis have sympotmatic seizures in the acute phase) or the time from seizure-free (without rescue therapy) to rescue therapy.	Up to 2 years post CT103A infusion
Other	AE: Change in CASE	The changes of Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score from baseline.	Up to 2 years post CT103A infusion
Other	AE: Change in MoCA	The changes of Montreal Cognitive Assessment Scale (MoCA) total scores from baseline.	Up to 2 years post CT103A infusion
Other	AE: Change in CGI	The changes of Total Clinical Global Impressions (CGI) score from baseline.	Up to 2 years post CT103A infusion
Other	AE: Change in GCS	The changes of Total Glasgow Coma Score (GCS) from baseline.	Up to 2 years post CT103A infusion
Other	AE: Change in MMSE	The changes of Total Minimum Mental State Examination Score (MMSE) from baseline.	Up to 2 years post CT103A infusion
Other	AE: Number of FBDS	The number of faciobrachial dystonic seizure (FBDS) in patients with LGI1 antibody-positive encephalitis.	Up to 2 years post CT103A infusion
Other	MOGAD: Annualized relapse rate	Annualized recurrence rate: The number of MOGAD relapses divided by observed year after CT103A cells infusion	Up to 2 years post CT103A infusion
Other	MOGAD: Time to first relapse	Time to first relapse: Time from CT103A infusion to the first relapse of MOGAD.	Up to 2 years post CT103A infusion
Other	MOGAD: MS: Number of T1 Gadolinium (Gd)	The changes of enhancing Lesions as detected by MRI.	Up to 2 years post CT103A infusion
Other	MOGAD: Change in EDSS	The changes of EDSS score from baseline.	Up to 2 years post CT103A infusion
Other	MOGAD: Change in MoCA	The changes of MOCA score from baseline.	Up to 2 years post CT103A infusion
Other	MOGAD: Change in MoCA	The changes of MMSE score from baseline.	Up to 2 years post CT103A infusion
Other	All patients: Change in mRS	The changes of mRS score from baseline.	Up to 2 years post CT103A infusion
Primary	Types and incidence of dose-limiting toxicity (DLT) after CT103A cells infusion	To evaluate the DLT occurred within 3 months after CT103A infusion	Up to 3 months post CT103A infusion
Primary	Incidence and severity of AEs, including changes in vital signs, physical examination, laboratory parameters, Electrocardiograms and Echocardiograms.	To evaluate the AEs occurred within 2 years after CT103A infusion	Up to 2 years post CT103A infusion
Secondary	PD-Soluble BCMA	The changes of concentration of soluble BCMA in the peripheral blood after CT103A infusion.	Up to 2 years post CT103A infusion
Secondary	PD-Pathogenic antibody	The changes of pathogenic antibody titers in peripheral blood or cerebrospinal fluid.	Up to 2 years post CT103A infusion
Secondary	PD-Nfl(MS)	The changes of peripheral blood Neurofilament Light chain (NfL) concentration in patients with MS.	Up to 2 years post CT103A infusion
Secondary	PK-VCN	The number of BCMA CAR gene copies (VCN,copies/µg DNA) in peripheral blood and cerebrospinal fluid after administration.	Up to 15 years post CT103A infusion
Secondary	PK-BCMA CAR-T cells	The concentration of BCMA CAR T cells (cells/mL) in peripheral blood after administration was detected by flow cytometry.	Up to 2 years post CT103A infusion